On Nov. 12, 2021, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2 Brilacidin COVID-19 clinical trial results to support Brilacidin’s potential inclusion in government-sponsored COVID-19 trials.

Topline results for the Phase 2 Brilacidin COVID-19 clinical trial have been reported. Complete analysis of trial results already had begun, with the aim to potentially identify positive trends in the data that could support Brilacidin for inclusion in larger COVID-19 platform trials, such as the U.K.’s CTAP program and the NIH’s ACTIV program.

The purpose of these programs was to prioritize development of promising COVID-19 therapeutics. Some COVID-19 drug candidates that did not meet their trial’s primary endpoint, for example Relief Therapeutics’ aviptadil, or those that showed inconclusive results in early clinical testing (e.g., anti-IL-6 drugs), have later gone on to be included in larger platform trials based on deeper analysis of trial results.

The Company’s intent, should full analysis of the Brilacidin COVID-19 trial results yield promising data, was to submit Brilacidin for inclusion in these larger COVID-19 platforms. Sufficient intravenous Brilacidin drug supply is on hand to support further clinical testing of Brilacidin in COVID-19.

Brilacidin is the only non-peptidic HDP-mimetic drug candidate to be evaluated in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19. Innovation Pharmaceuticals is developing Brilacidin for the treatment of COVID-19 under FDA Fast Track designation. A dual-acting inhibitor able to target viral proteins and host factors, while also exhibiting robust anti-inflammatory and antibacterial properties, Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses and bunyaviruses (with lab testing against other viruses also underway), supporting Brilacidin’s development as a broad-spectrum antiviral.